



## Locoid® (hydrocortisone butyrate) 0.1% lotion – First-time generic

- On November 22, 2017, [Teligent announced](#) the FDA approval of their [AB-rated](#) generic version of Valeant's [Locoid \(hydrocortisone butyrate\)](#) 0.1% lotion for the topical treatment of mild to moderate atopic dermatitis in patients  $\geq$  3 months of age.

Teligent plans to launch hydrocortisone butyrate 0.1% lotion in in the first quarter of 2018.

- Hydrocortisone butyrate is currently available generically as a [cream](#), [lipid cream](#), ointment, and topical solution.

— Refer to individual drug labels for more indication information.

- Based on IMS Health data from September 2017, the total addressable market for Locoid lotion is approximately \$17 million.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.